NovaSure System Research Articles

Predictors of Long-Term NovaSure Endometrial Ablation Failure

Study ObjectiveEndometrial ablation using the NovaSure system (Hologic Inc., Marlborough, MA) is 1 of the treatment options for heavy menstrual bleeding (HMB), which has a reported success rate of 81% to 90%. We aimed to identify predictors for NovaSure endometrial ablation failure. This will contribute to a more effective and individualized preoperative counseling. DesignA retrospective multicenter cohort study (Canadian Task Force classification II-2). SettingOne university hospital and 1 large teaching hospital. PatientsFour hundred eighty-six patients with HMB who had undergone NovaSure endometrial ablation between 2008 and 2014. InterventionsThe NovaSure endometrial ablation system for patients with HMB. Measurements and Main ResultsIn total, the required characteristics of 486 patients were collected and analyzed. With a median follow-up of 45 months, 19.3% (n = 94) required a secondary treatment and thus were considered NovaSure failures. Multivariate logistic regression analysis showed that younger age (p = .019), a history of sterilization (p = .002), the presence of dysmenorrhea (p < .001) and the presence of an intramural leiomyoma on transvaginal sonography (p = .005) were independent predictors of NovaSure ablation failure. Preoperative hysteroscopy appeared to be a protective factor (p = .001). ConclusionWithin a median follow-up of 45 months, 19.3% of patients required a secondary treatment. Identification of specific predictive factors for endometrial ablation failure is important in preoperative counseling and patient selection. In the current era of personalized medicine, doctors and patients will ideally choose the therapy that results in the highest chance of success in the individual case.

Radiofrequency-induced endometrial ablation for the treatment of postpartum hemorrhage after vaginal delivery: Case report.

Rationale:Postpartum hemorrhage is a common complication and difficult problem in obstetrics. Radiofrequency-induced endometrial ablation (RFIEA) widely used in abnormal uterine bleeding and achieved good effects. This article will investigate the effect of RFIEA for treatment of postpartum hemorrhage.Patients concerns:A 26-year-old healthy full-term parturient woman presented with postpartum hemorrhage after vaginal delivery for 11 hours, who was ready to emergency surgery (hysterectomy) 7 hours after inserting an intrauterine balloon into uterine cavity.Diagnoses:Blood loss after vaginal delivery was more than 500 mL during 11 hours in the full-term parturient woman.Intervention:We applied RFIEA to treatment of postpartum hemorrhage. With the patient in dorsal lithotomy position, we advanced the disposable device according to the instruction and operated the Novasure system in semi-automatic mode.Outcomes:There was no obvious endometrial bleeding found with hysteroscopy at the end of surgery. No complications (such as thermal injury to adjacent tissue, uterine perforation, bowel perforation) were observed.Lessons:It is safe and effective to treat postpartum hemorrhage after vaginal delivery using RFIEA.

Clinical efficacy of NovaSure for 30 patients with adenomyosis

To investigate the efficacy and safety of NovaSure system for dysmenorrhea and abnormal uterine bleeding of adenomyosis. A retrospective analysis on 30 patients with adenomyosis, who treated by NovaSure, were carried out. We collected related clinical data before operation and collected postoperative information about dyemenorrhea, menstruation, anemia and uterine volume by visiting outpatient or telephone. All patients were followed up for 7 to 31 months after the operation. The relief rate of menstrual pain was 83.3%. All patients got obvious improvements in menstruation and anemia (P<0.05). After operation, uterine volume was significantly decreased (P<0.05). Only one case received intervention in 2 years (3.3%). NovaSure can relieve symptoms of menorrhagia and alleviate dysmenorrhea symptoms. It is a new way for the treatment of uterine adenomyosis.

Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives.

ObjectivesAbnormal uterine bleeding (AUB) interferes with physical, emotional, and social well-being, impacting the quality of life of more than 10 million women in the USA. Hysterectomy, the most common surgical treatment of AUB, has significant morbidity, low mortality, long recovery, and high associated health care costs. Global endometrial ablation (GEA) provides a surgical alternative with reduced morbidity, cost, and recovery time. The NovaSure® system utilizes unique radiofrequency impedance-based GEA technology. This study evaluated cost effectiveness of AUB treatment with NovaSure ablation versus other GEA modalities and versus hysterectomy from the US commercial and Medicaid payer perspectives.MethodsA health state transition (semi-Markov) model was developed using epidemiologic, clinical, and economic data from commercial and Medicaid claims database analyses, supplemented by published literature. Three hypothetical cohorts of women receiving AUB interventions were simulated over 1-, 3-, and 5-year horizons to evaluate clinical and economic outcomes for NovaSure, other GEA modalities, and hysterectomy.ResultsModel analyses show lower costs for NovaSure-treated patients than for those treated with other GEA modalities or hysterectomy over all time frames under commercial payer and Medicaid perspectives. By Year 3, cost savings versus other GEA were $930 (commercial) and $3,000 (Medicaid); cost savings versus hysterectomy were $6,500 (commercial) and $8,900 (Medicaid). Coinciding with a 43%–71% reduction in need for re-ablation, there were 69%–88% fewer intervention/reintervention complications for NovaSure-treated patients versus other GEA modalities, and 82%–91% fewer versus hysterectomy. Furthermore, NovaSure-treated patients had fewer days of work absence and short-term disability. Cost-effectiveness metrics showed NovaSure treatment as economically dominant over other GEA modalities in all circumstances. With few exceptions, similar results were shown for NovaSure treatment versus hysterectomy.ConclusionModel results demonstrate strong financial favorability for NovaSure ablation versus other GEA modalities and hysterectomy from commercial and Medicaid payer perspectives. Results will interest clinicians, health care payers, and self-insured employers striving for cost-effective AUB treatments.

Endometrial ablation with the NovaSure system in Iran

Objective To evaluate the rate of response to treatment with the NovaSure endometrial ablation device among Iranian women with menorrhagia. Methods Twenty 35–50-year-old women with menorrhagia who were referred to Arash Hospital, Tehran, Iran, in 2008 were enrolled. They underwent endometrial ablation via the NovaSure system and were followed-up for 2 years. Results The incidence of amenorrhea was 30.0% at the end of the 2-year follow-up period. Hypomenorrhea was reported by 40.0% of women. The mean number of days of bleeding per month decreased significantly, from 30.0 ± 6.4 days before treatment to 3.1 ± 2.6 days after 2 years ( P < 0.001). The severity of bleeding decreased significantly within 2 years after treatment ( P < 0.001). In total, 85.0% of women were satisfied and 90.0% had responded to treatment—as defined by amenorrhea, hypomenorrhea, or return to normal menstruation. Conclusion The NovaSure system is effective and should be considered by gynecologists for the treatment of menorrhagia.

NovaSure impedance controlled system for endometrial ablation: The experience of the first UK reference centre

SummaryIn this study we assessed the effectiveness of the NovaSure Impedance Controlled Endometrial Ablation System for the treatment of menorrhagia in pre-menopausal women. A total of 125 pre-menopausal women with menorrhagia, which was secondary to dysfunctional uterine bleeding and unresponsive to medical therapy, had endometrial ablation using the NovaSure system between June 2004 and October 2005. A postal questionnaire was sent to all patients and the response rate was 80% (110 patients). The clinical data were analysed in 105 case notes (84%). The mean age was 43.91 ± 5.45 SD, and mean parity was 2.09 ± 0.65. The median treatment time was 71.00 s, ranging between 45.00 and 105.00 s. Results from a period of 18 months demonstrated that the NovaSure system was effective in reducing excessive uterine blood loss in 90.5% of patients and there were no intraoperative adverse events reported. Some 87% of patients were satisfied with the procedure and 90% of patients would be happy to recommend the treatment. We conclude that the NovaSure system is effective and safe in the treatment of symptomatic menorrhagia.

NovaSure impedance controlled endometrial ablation: Long-term follow-up results

Study objective A 7-year follow-up evaluation of the safety, efficacy, and long-term outcome of endometrial ablation when using the NovaSure system in patients with menorrhagia secondary to abnormal uterine bleeding (AUB). Design Prospective, single-arm study (Canadian Task Force classification II-1). Setting St. Imre Teaching Hospital, Budapest, Hungary. Patients Seventy-five premenopausal women with menorrhagia secondary to AUB. Interventions Endometrial ablation using the NovaSure System without the use of endometrial pretreatment. Measurements and main results Loss of menstrual blood was measured using pictorial blood loss assessment chart diaries. Treatment times, complications, and rate of surgical re-interventions were recorded. No intra or postoperative complications were noted. Median follow-up period at the time was 7.8 years (range 6–8.6 years). The proportion of patients with fewer than 7 and 7 or more years of follow-up was 28.8% and 71.2%, respectively. The median treatment time was 92 seconds (range 40–120 seconds). At 7-year follow-up, 97.1% of evaluable patients reported amenorrhea. However, all patients (100%, actuarial rate: 97% with 95% CI [83%–100%]) experienced a successful reduction in bleeding to normal levels or less. Six of 75 patients underwent hysterectomy, and one of 75 had a repeat ablation representing a total of 92% (95% CI: 83%–96%) avoidance of additional surgery during the follow-up period. Conclusions Clinical results demonstrate that the use of NovaSure System is safe and effective, with a low rate of surgical re-intervention at 7-year follow-up.

Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study

Study objective To assess the safety and effectiveness of the NovaSure Impedance Controlled Endometrial Ablation System for the treatment of excessive uterine bleeding in premenopausal and postmenopausal women with intracavitary disease (polyps or myomas) up to 3 cm. Design Prospective, single-arm study. (Canadian Task Force Classification II-2.) Setting Academic medical center. Patients This clinical study was conducted in 65 women with menometrorrhagia with confirmed (type I and II) submucous myomas up to 3 cm with and without polyps. Intervention Patients were treated with the NovaSure System and received no hormonal or mechanical pretreatment to thin the endometrial lining or as a uterine pathologic condition shrinking agent. Measurements and main results All patients were diagnosed with intracavitary disease during office hysteroscopy. Patients completed menstrual questionnaires at the initial screening and at 1 year after treatment. Twelve-month results demonstrated that the NovaSure System was effective in reducing excessive uterine blood loss. Success (defined as reduction to normal bleeding) was observed in 95% (95% CI: 86%–99%) of patients, with 69% (95% CI: 56%–80%) reporting amenorrhea at 1 year after treatment. The median treatment time (time of energy delivery) was 78 seconds (range 61–120 seconds). All patients underwent the procedure under local or intravenous sedation. No intraoperative or postoperative adverse events were reported. There was a significant decrease in premenstrual symptoms and dysmenorrhea at 12 months after the procedure. Ninety-five percent (95% CI: 86%–99%) of patients were satisfied with the procedure. Conclusion Clinical results of this study demonstrate that the NovaSure System is safe and effective in treatment of patients with menometrorrhagia caused by intracavitary disease up to 3 cm.

188: Novasure Impedance Controlled Endometrial Ablation System. Long-Term Follow-Up Results

Study ObjectiveAssess the efficacy and safety of the NovaSure system in women with severe menorrhagia secondary to DUB.DesignA prospective, single-arm, pilot study.SettingSt. Imre Teaching Hospital, Budapest, Hungary.PatientsSeventy-five pre-menopausal women with menorrhagia secondary to DUB.InterventionEndometrial ablation using NovaSure Impedance Controlled Endometrial Ablation System.Measurements and Main ResultsNo intra-operative or post-operative complications were observed. Treatment time averaged 90 seconds. The results over the course of follow-up are as follows: at 12 (n=75), 24 (n=74), 36 (n=69), 48 (n=68), 60 (n=57), 72 (n=41) and 84 (n=21) months of follow-up amenorrhea was reported by 72%, 73%, 75%, 75%, 82%, 90% and 95% of patients, with reduction in bleeding to normal or less observed in 96%, 98%, 100%, 100%, 98%, 100% and 100% respectively. Six patients (all treatment successes) underwent hysterectomy due to pelvic pain. Five were diagnosed with adenomyosis and/or endometriosis and one with fibroids. One patient underwent a repeat (rollerball) ablation.ConclusionLong-term follow-up results demonstrate that the NovaSure procedure is very effective and allows for sound data durability. Hysterectomy due to menorrhagia was avoided in 100% of cases and in 92% of cases for all other reasons. Additional long term follow-up data will be available and presented at the time of the meeting. Study ObjectiveAssess the efficacy and safety of the NovaSure system in women with severe menorrhagia secondary to DUB. Assess the efficacy and safety of the NovaSure system in women with severe menorrhagia secondary to DUB. DesignA prospective, single-arm, pilot study. A prospective, single-arm, pilot study. SettingSt. Imre Teaching Hospital, Budapest, Hungary. St. Imre Teaching Hospital, Budapest, Hungary. PatientsSeventy-five pre-menopausal women with menorrhagia secondary to DUB. Seventy-five pre-menopausal women with menorrhagia secondary to DUB. InterventionEndometrial ablation using NovaSure Impedance Controlled Endometrial Ablation System. Endometrial ablation using NovaSure Impedance Controlled Endometrial Ablation System. Measurements and Main ResultsNo intra-operative or post-operative complications were observed. Treatment time averaged 90 seconds. The results over the course of follow-up are as follows: at 12 (n=75), 24 (n=74), 36 (n=69), 48 (n=68), 60 (n=57), 72 (n=41) and 84 (n=21) months of follow-up amenorrhea was reported by 72%, 73%, 75%, 75%, 82%, 90% and 95% of patients, with reduction in bleeding to normal or less observed in 96%, 98%, 100%, 100%, 98%, 100% and 100% respectively. Six patients (all treatment successes) underwent hysterectomy due to pelvic pain. Five were diagnosed with adenomyosis and/or endometriosis and one with fibroids. One patient underwent a repeat (rollerball) ablation. No intra-operative or post-operative complications were observed. Treatment time averaged 90 seconds. The results over the course of follow-up are as follows: at 12 (n=75), 24 (n=74), 36 (n=69), 48 (n=68), 60 (n=57), 72 (n=41) and 84 (n=21) months of follow-up amenorrhea was reported by 72%, 73%, 75%, 75%, 82%, 90% and 95% of patients, with reduction in bleeding to normal or less observed in 96%, 98%, 100%, 100%, 98%, 100% and 100% respectively. Six patients (all treatment successes) underwent hysterectomy due to pelvic pain. Five were diagnosed with adenomyosis and/or endometriosis and one with fibroids. One patient underwent a repeat (rollerball) ablation. ConclusionLong-term follow-up results demonstrate that the NovaSure procedure is very effective and allows for sound data durability. Hysterectomy due to menorrhagia was avoided in 100% of cases and in 92% of cases for all other reasons. Additional long term follow-up data will be available and presented at the time of the meeting. Long-term follow-up results demonstrate that the NovaSure procedure is very effective and allows for sound data durability. Hysterectomy due to menorrhagia was avoided in 100% of cases and in 92% of cases for all other reasons. Additional long term follow-up data will be available and presented at the time of the meeting.

NovaSure Bipolar Radiofrequency Endometrial Ablation: Report of 200 Cases

Objective: To review the perioperative complications and short-term outcome in women undergoing endometrial ablation for menorrhagia using the NovaSure bipolar radiofrequency impedance-controlled system.Methods: We conducted a prospective observational study of endometrial ablation using the NovaSure system in 200 women with menorrhagia not amenable to medical management.Results: Of the 200 women treated, 146 have been observed for 1 to 4 years with the following outcomes related to menstrual bleeding: amenorrhea 43.1 %, light bleeding 41.8%, normal bleeding 4.1 %, and heavy bleeding 11 %. Twelve of the 146 women (8.2%) required repeat surgical treatment: hysterectomy in 10 cases and repeat ablation in 2. In the 200 cases, 1 laparoscopy was performed because of uterine perforation at the time of pretreatment hysteroscopy, and 2 patients required antibiotic therapy for postoperative endomyometritis. Of the women observed for 1 to 4 years, 81.5% felt the procedure was successful, and 97.3% would recommend the procedure to a friend.Conclusion: Endometrial ablation using the NovaSure system is a simple technique in the normal uterine cavity, which can be performed under local anaesthesia and conscious sedation. The complication rate is low, and the short-term satisfaction and results are good.

NovaSure impedance controlled system for endometrial ablation: Three-year follow-up on 107 patients

Objective This study was undertaken to assess the safety, efficacy, and data durability of the NovaSure ablation at 3 years after the procedure in women with menorrhagia secondary to dysfunctional uterine bleeding (DUB). Study design A prospective, single-arm, observational pilot study (Canadian Task Force classification II-1) was carried out at a specialized center for gynecologic endoscopy with 107 premenopausal women with menorrhagia secondary to DUB. NovaSure ablation was performed in 107 patients. Pictorial Blood loss Assessment Chart diary sampling was used to assess menstrual blood loss. Ablation was performed without any type of endometrial pretreatment. Results No intraoperative or postoperative complications were observed. Treatment time averaged 94 seconds; 65% of the patients reported amenorrhea. Hysterectomy was avoided in 97.2% of patients at 3-year follow-up. Conclusion Long-term clinical results demonstrate that the NovaSure system is a safe and effective method for treatment of women with menorrhagia secondary to DUB, yielding high amenorrhea and success rates, with low re-treatment rates.

Use of Novasure endometrial ablation system in an office setting environment

Use of Novasure endometrial ablation system in an office setting environment

One-Year follow-up results with the use of the novasure system in patients with submucous myomas

One-Year follow-up results with the use of the novasure system in patients with submucous myomas

Comparison of the clinical performance of NovaSure and ThermaChoice endometrial ablation

Objective. To assess the anlenorrhea rates, satisfaction, quality of life and costs associated with the NovaSure procedure in comparison with ThemlaChoice balloon ablation. Design. Randomised, double-blind, study. Setting. Teaching Hospital. Patients. A total of 126 pre-menopansal women suffering from menorrhagia with the PBLAC > 150 or more. Interventions. NovaSure Bipolar radiofrequency ablation and ThermaChoice hot water balloon ablation. The NovaSure System consists of a 3-Dimensional Bipolar Device and RF Controller that enable endometrial ablation in an average of 90 seconds without the need for endometrial pretreatment. Them~aChoice consists of a latex balloon with a thermistor inside. Measurements and Main Results. PBAC, FSH levels and additional surgical interventions were evaluated at 3, 6, and 12 months. Quality of life evaluation was assessed before the intervention and at to 2 days, 2 weeks 3, 6 and 12 months after the ablation treatment. At 6-months followup the NovaSure group of patients reported an amenorrhoea rate of 54%, compared to 8% in the ThermaChoice group. At 12 months follow-up the an~enorrhea rate in the NovaSure arm was 55% compared to 12% in the ThermaChoice arm. No complications were associated with either procedure. An evaluation of direct and indirect costs was made. Conclusion. Clinical results demonstrate that the NovaSure System is an effective and safe second-generation device, yielding significantly higher amenorrhea and success rates when compared to ThermaChoice.

Preliminary clinical results with the use of the novasure system in patients with submucous fibroids

Preliminary clinical results with the use of the novasure system in patients with submucous fibroids

Assessment and Comparison of Intraoperative and Postoperative Pain Associated with NovaSure and ThermaChoice Endometrial Ablation Systems

Study Objective To assess and compare intraoperative and postoperative pain associated with NovaSure impedance-controlled endometrial ablation system and ThermaChoice system. Design Prospective, international, multicenter, double-arm study (Canadian Task Force classification II-1). Setting Academic medical centers and private offices. Patients Sixty-seven premenopausal women with menorrhagia. Intervention Endometrial ablation with either the NovaSure (37 women) or ThermaChoice (30) system. NovaSure-treated patients received no endometrial pretreatment; those treated with ThermaChoice received the recommended 3-minute suction dilatation and curettage. Measurements and Main Results Standard pain measurement instruments (visual analog scale, numeric rating scale) were used to assess intraoperative and postoperative pain. Serum levels of prostaglandin-F 2α were measured before and 5, 30, and 60 minutes after the procedure. Patients treated with the NovaSure system reported statistically significantly lower intraoperative and postoperative pain than those treated with the ThermaChoice system (p <0.0001). Procedure time was statistically significantly shorter with the NovaSure system (p <0.0001). Prostaglandin-F 2α values did not differ statistically between groups. Conclusion The NovaSure system is associated with statistically significantly lower intraoperative and postoperative pain than ThermaChoice system, and endometrial ablation with NovaSure could become an office-based procedure.

A Randomized, Multicenter Trial of Safety and Efficacy of the NovaSure System in the Treatment of Menorrhagia

Study Objective To compare the safety and effectiveness of the NovaSure impedance-controlled endometrial ablation system with hysteroscopic wire loop resection plus rollerball ablation for treatment of excessive uterine bleeding in premenopausal women. Design Randomized, multicenter, double-arm study (Canadian Task Force classification I). Setting Nine academic medical centers and private offices. Patients Two hundred sixty-five premenopausal women with symptomatic menorrhagia. Intervention Ablation performed with the NovaSure system or wire loop resection and rollerball. Measurements and Main Results Success [pictorial blood loss-assessment chart (PBLAC) score ≤75] was achieved in 88.3% of NovaSure-treated and 81.7% of rollerball-treated patients. One year after treatment 90.9% and 87.8%, respectively, reported normal bleeding or less (PBLAC ≤100) and 41% and 35%, respectively, experienced amenorrhea (PBLAC = 0). Mean procedure time was 4.2 minutes (average 84 sec) in the NovaSure group and 24.2 minutes in the rollerball group. Local and/or intravenous sedation was administered in 73% of NovaSure patients and 18% of rollerball patients. Intraoperative adverse events occurred less frequently with NovaSure (0.6%) than with rollerball (6.7%). Postoperative adverse events occurred in 13% and 25.3% of patients, respectively. Conclusion The NovaSure system was safe and effective in treatment of women with menorrhagia. The procedure is both quick and effective, and eliminates the expense and side effects of endometrial pretreatment.

NovaSure Impedance-Controlled System for Endometrial Ablation

Study Objective To assess the efficacy and safety of the NovaSure endometrial ablation system in women with severe dysfunctional uterine bleeding (DUB). Study Design Prospective, single-arm, controlled, observational pilot study (Canadian Task Force classification II-1). Setting Free-standing center for gynecologic endoscopy. Patients One hundred seven premenopausal women whose menorrhagia was unresponsive to medical therapy, who had completed childbearing, and who had undistorted uterine cavities. Intervention Endometrial ablation with the NovaSure system. Measurements and Main Results Diaries were used to qualify patients for the study, as well as for posttreatment evaluation of menstrual blood loss and bleeding pattern (amenorrhea, spotting, hypomenorrhea, eumenorrhea, menorrhagia). No drug or mechanical endometrial pretreatment was administered. Position of the uterus was not a factor in patient selection. No intraoperative or postoperative complications occurred. Treatment time averaged 94 seconds. Of 107 women, 106 completed 6 months of follow-up and 105 had 12 months. Amenorrhea was 46% and 58%, respectively. Conclusion The NovaSure System is safe and is effective in treating women with DUB. Endometrial pretreatment is not necessary, and presence of blood in the uterine cavity during treatment is not a limiting factor.

Is endometrial pretreatment necessary in NovaSure™ 3‐D endometrial ablation?

ObjectiveTo assess and compare the efficacy of NovaSure, a novel 3‐D bipolar endometrial ablation system, for women with severe menorrhagia secondary to dysfunctional uterine bleeding (DUB), with and without endometrial preparation.Study designA prospective, double‐arm, controlled, observational pilot study of 40 women undergoing endometrial ablation using the NovaSure system.Patients40 premenopausal women, of average age 44 years, with menorrhagia secondary to DUB and unresponsive to medical therapy, who had completed childbearing, with non‐distorted uterine cavities, and cornu‐to‐cornu measurement of greater than 2.5 cm.InterventionsEndometrial ablation using the 3‐D bipolar NovaSure system.Methods50% of the patients received gonadotrophin‐releasing hormone (GnRH) agonist for endometrial thinning. The remaining patients received no treatment for endometrial thinning. Pictorial blood assessment chart (PBLAC) diary sampling was used to select patients for the study, as well as to conduct the post‐treatment evaluation of menstrual blood loss and bleeding pattern (amenorrhoea, spotting, hypomenorrhea, eumenorrhoea or menorrhagia). All patients received the treatment under intravenous sedation with paracervical block.ResultsNo intraoperative complications were observed. Treatment time averaged 72 seconds. Follow up of 12 months has been completed in 29 patients. No significant difference was observed in the outcome (i.e. efficacy) of the procedure between the two groups of patients.ConclusionsPreliminary results indicate that the NovaSure system can be successfully used as an effective method of treatment for women with menorrhagia secondary to DUB. Endometrial pretreatment appears not to be necessary in global ablation performed using the NovaSure system.

The novasure system for endometrial ablation

International Journal of Gynecology & ObstetricsVolume 70, Issue S1 p. A25-A25 Endometrial ablations The novasure system for endometrial ablation J.M. Cooper, J.M. CooperSearch for more papers by this author J.M. Cooper, J.M. CooperSearch for more papers by this author First published: 09 December 2003 https://doi.org/10.1016/S0020-7292(00)82028-7AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume70, IssueS12000Pages A25-A25 RelatedInformation